X

Vous n'êtes pas connecté

Rubriques :

  - DRUGS.COM - Clinical Trials News - 10/07/2024 01:07

Expanded HyBryte Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

PRINCETON, N.J., July 9, 2024 /PRNewswire/ -- Soligenix, Inc., (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need...

Articles similaires

Sorry! Image not available at this time

Prescient advances new therapies for hard-to-treat cancers

stockhead.com.au - 27/Jun 04:24

Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, including cutaneous T-Cell lymphoma (CTCL). ...

Sorry! Image not available at this time

Prescient advances new therapies for hard-to-treat cancers

stockhead.com.au - 27/Jun 04:24

Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, including cutaneous T-Cell lymphoma (CTCL). ...

Sorry! Image not available at this time

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

mangaloremirror.com - 02/Jul 11:56

BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage...

Sorry! Image not available at this time

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-Positive NSCLC

drugs.com - 24/Jun 00:06

CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating...

Sorry! Image not available at this time

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-Positive NSCLC

drugs.com - 24/Jun 00:06

CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating...

Sorry! Image not available at this time

Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH

drugs.com - 24/Jun 03:07

CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 24, 2025 /PRNewswire/ -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical...

Sorry! Image not available at this time

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

drugs.com - 24/Jun 00:06

ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late...

Sorry! Image not available at this time

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

drugs.com - 24/Jun 00:06

ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late...

Sorry! Image not available at this time

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

mangaloremirror.com - 30/Jun 11:55

First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain...

Sorry! Image not available at this time

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

mangaloremirror.com - 30/Jun 11:55

First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain...

Les derniers communiqués